Примери за използване на This indication на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The CHMP also discussed this indication.
Therefore this indication was removed.
There were three pivotal studies supporting this indication.
The CHMP considered this indication to be approvable.
This indication may be included in the batch or serial number;
Хората също превеждат
The CHMP therefore recommended the removal of this indication.
This indication is based exclusively on tradition and many years of experience.
The CHMP considered all the studies submitted for this indication.
This indication is based exclusively on tradition and many years of experience.
It is the first immunotherapy approved for this indication.
This indication shall appear in the same visual field as the legal name.
We are, however, highly grateful for this indication offriendship.".
And so this indication, in Goldman's view, shows a labor market coming back into balance.
The CHMP asked the MAH to submit evidence to support this indication.
The use of the product in this indication in children below 2 years is not investigated.
The CHMP considered the benefit/ risk ratio of this indication is positive.
This indication is approved for both tablets and IV formulation of levofloxacin.
Only limited evidence of efficacy in this indication is available.
This indication is primarily based on the results of the clinical trials ELITE I and II.
Therefore the harmonised wording for this indication is“Treatment of schizophrenia”.
In addition, the FDA granted Breakthrough Therapy Designation for this indication.
Therefore the CHMP considered this indication no longer appropriate for amoxicillin.
Very limited information exists on the efficacy of tolperisone in this indication.
The best way to use Viraferon in this indication is in combination with ribavirin.
The CHMP acknowledged the arguments andagreed that Augmentin is suitable for this indication.
This indication does not make any more reference to individual forms of invasive candidal infections.
The analysis results show a favorable safety drug profile for this indication.
This indication shall be without prejudice to the question of the principal contractor's responsibility.
Therefore, the CHMP is of opinion that this indication is not supported due to lack of appropriate data.